Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.

Also called NCT06347003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 446 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06347003
  • EudraCT 2023-509300-14
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Hungary, Italy, Poland, Romania, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06347003. Randomized; quadruple masking; primary purpose treatment. Start 2024-07-22 (actual); primary completion 2026-06-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Acronym
SHASTA-3
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Plozasiran Injection
Intervention (Drug)
Placebo
Lead sponsor
Arrowhead Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06347003
Content hash
1910cf8efdc5dc8bc9cb3aad3b6dcfb4c0df32ce704f974077a0a786f3ff32c4